Cholesteryl ester transfer protein gene haplotypes, plasma high-density lipoprotein levels and the risk of coronary heart disease

High-density lipoprotein cholesterol (HDL-C) is a known inverse predictor of coronary heart disease (CHD) and is thus a potential therapeutic target. Cholesteryl ester transfer protein (CETP) is a key protein in HDL-C metabolism such that elevated CETP activity is associated with lower HDL-C. Currently available HDL-C raising drugs are relatively ineffective and evidence suggesting the role of CETP in HDL-C levels has promoted the development of CETP inhibitors as potential therapeutic agents for CHD. We investigated three SNPs in the CETP gene in two cross-sectional community-based populations (n = 1,574 and 1,109) and a population of 556 CHD patients to determine if reduced CETP activity due to genetic variations in the CETP gene would increase HDL-C levels and reduce the risk of CHD. CETP genotypes and haplotypes were tested for association with lipid levels, CETP activity and risk of CHD. Multivariate analysis showed the common AAB2 haplotype defined by the G-2708A, C-629A and TaqIB polymorphisms, was consistently associated with reduced CETP activity and increased HDL-C levels. A mean increase in HDL-C levels of 0.16–0.24 mmol/l was observed in individuals with two copies of the AAB2 haplotype relative to non AAB2 carriers across all three populations (P < 0.001). A case-control study of males indicated no association between single SNPs or haplotypes and the risk of CHD. These results suggest that raising HDL-C via CETP inhibition may not alter risk of CHD. Randomized control trials are needed to determine whether CETP inhibition will in reality reduce risk of CHD by raising HDL-C.

[1]  A. Tall,et al.  Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins , 1989, Nature.

[2]  D. Gordon,et al.  High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. , 1989, Circulation.

[3]  A. Tall,et al.  Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. , 1990, The New England journal of medicine.

[4]  E. Thompson,et al.  Performing the exact test of Hardy-Weinberg proportion for multiple alleles. , 1992, Biometrics.

[5]  G. Assmann,et al.  Mutagenically separated PCR (MS-PCR): a highly specific one step procedure for easy mutation detection. , 1993, Nucleic acids research.

[6]  M. Savolainen,et al.  DNA polymorphisms at the locus for human cholesteryl ester transfer protein (CETP) are associated with macro‐ and microangiopathy in non‐insulin‐dependent diabetes mellitus , 1994, Clinical genetics.

[7]  D. Arveiler,et al.  Alcohol intake modulates the effect of a polymorphism of the cholesteryl ester transfer protein gene on plasma high density lipoprotein and the risk of myocardial infarction. , 1995, The Journal of clinical investigation.

[8]  Laurent Excoffier,et al.  Testing for linkage disequilibrium in genotypic data using the Expectation-Maximization algorithm , 1996, Heredity.

[9]  S. Yamashita,et al.  Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[10]  J. Beilby,et al.  Hyperhomocysteinemia but Not the C 677 T Mutation of Methylenetetrahydrofolate Reductase Is an Independent Risk Determinant of Carotid Wall Thickening , 1999 .

[11]  J. Olynyk,et al.  A population-based study of the clinical expression of the hemochromatosis gene. , 1999, The New England journal of medicine.

[12]  V. Gudnason,et al.  Cholesteryl ester transfer protein gene effect on CETP activity and plasma high‐density lipoprotein in European populations , 1999, European journal of clinical investigation.

[13]  OdettePoirier,et al.  New Functional Promoter Polymorphism, CETP/−629, in Cholesteryl Ester Transfer Protein (CETP) Gene Related to CETP Mass and High Density Lipoprotein Cholesterol Levels , 2000 .

[14]  J. Ordovás,et al.  Genetic Polymorphisms and Activity of Cholesterol Ester Transfer Protein (CETP): Should We Be Measuring Them? , 2000, Clinical chemistry and laboratory medicine.

[15]  K. Wakitani,et al.  A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits , 2000, Nature.

[16]  B. Nordestgaard,et al.  Common Cholesteryl Ester Transfer Protein Mutations, Decreased HDL Cholesterol, and Possible Decreased Risk of Ischemic Heart Disease: The Copenhagen City Heart Study , 2000, Circulation.

[17]  V. Gudnason,et al.  The -629C>A polymorphism in the CETP gene does not explain the association of TaqIB polymorphism with risk and age of myocardial infarction in Icelandic men. , 2001, Atherosclerosis.

[18]  M. Xiong,et al.  Haplotypes vs single marker linkage disequilibrium tests: what do we gain? , 2001, European Journal of Human Genetics.

[19]  A. Rantala,et al.  Variation at the cholesteryl ester transfer protein gene in relation to plasma high density lipoproteins cholesterol levels and carotid intima‐media thickness , 2001, European journal of clinical investigation.

[20]  J. Beilby,et al.  Polymorphisms in the angiotensinogen gene are associated with carotid intimal-medial thickening in females from a community-based population. , 2001, Atherosclerosis.

[21]  J. Reich,et al.  Single Nucleotide Polymorphism Haplotypes in the Cholesteryl-Ester Transfer Protein (CETP) Gene and Lipid Phenotypes , 2003, Human Heredity.

[22]  P. Ridker,et al.  A prospective study of TaqIB polymorphism in the gene coding for cholesteryl ester transfer protein and risk of myocardial infarction in middle-aged men. , 2002, Atherosclerosis.

[23]  H. Mabuchi,et al.  Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. , 2002, Clinical science.

[24]  Laurent Essioux,et al.  Common haplotypes in five genes influence genetic variance of LDL and HDL cholesterol in the general population. , 2002, Human molecular genetics.

[25]  L. Petit,et al.  Regulation of human CETP gene expression: role of SP1 and SP3 transcription factors at promoter sites -690, -629, and -37. , 2003, Journal of lipid research.

[26]  M Nauck,et al.  Haplotypes of the cholesteryl ester transfer protein gene predict lipid-modifying response to statin therapy , 2003, The Pharmacogenomics Journal.

[27]  F. Cambien,et al.  Common genetic variation of the cholesteryl ester transfer protein gene strongly predicts future cardiovascular death in patients with coronary artery disease. , 2003, Journal of the American College of Cardiology.

[28]  P. Barter,et al.  High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. , 2003, Atherosclerosis.

[29]  A. Zwinderman,et al.  Haplotype analysis of the CETP gene: not TaqIB, but the closely linked -629C-->A polymorphism and a novel promoter variant are independently associated with CETP concentration. , 2003, Human molecular genetics.

[30]  A. Lusis.  Genetic factors in cardiovascular disease. 10 questions. , 2003, Trends in cardiovascular medicine.

[31]  Johnf . Thompson,et al.  Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease Published, JLR Papers in Press, March 16, 2003. DOI 10.1194/jlr.R200018-JLR200 , 2003, Journal of Lipid Research.

[32]  T. Okamura,et al.  Haplotype analyses of cholesteryl ester transfer protein gene promoter: a clue to an unsolved mystery of TaqIB polymorphism , 2003, Journal of Molecular Medicine.

[33]  S. Ebrahim,et al.  'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? , 2003, International journal of epidemiology.

[34]  Nilesh J Samani,et al.  Genotypes and haplotypes predisposing to myocardial infarction: a multilocus case-control study. , 2004, European heart journal.

[35]  J. Kastelein,et al.  A review of CETP and its relation to atherosclerosis Published, JLR Papers in Press, September 1, 2004. DOI 10.1194/jlr.R400007-JLR200 , 2004, Journal of Lipid Research.

[36]  K. Watson,et al.  Anti-Inflammatory Properties of HDL , 2004, Reviews in Endocrine and Metabolic Disorders.

[37]  J. Reich,et al.  Haplotypes and SNPs in 13 lipid-relevant genes explain most of the genetic variance in high-density lipoprotein and low-density lipoprotein cholesterol. , 2004, Human molecular genetics.

[38]  P J Talmud,et al.  Cholesteryl Ester Transfer Protein TaqIB Variant, High-Density Lipoprotein Cholesterol Levels, Cardiovascular Risk, and Efficacy of Pravastatin Treatment: Individual Patient Meta-Analysis of 13 677 Subjects , 2005, Circulation.

[39]  P. Shah,et al.  Increasing High-Density Lipoprotein Cholesterol in Dyslipidemia by Cholesteryl Ester Transfer Protein Inhibition: An Update for Clinicians , 2005, Circulation.

[40]  B. Wolffenbuttel,et al.  The effect of cholesteryl ester transfer protein -629C->A promoter polymorphism on high-density lipoprotein cholesterol is dependent on serum triglycerides. , 2005, The Journal of clinical endocrinology and metabolism.

[41]  Kim W. Carter,et al.  JLIN: A java based linkage disequilibrium plotter , 2006, BMC Bioinformatics.

[42]  K W Carter,et al.  The C‐480T hepatic lipase polymorphism is associated with HDL‐C but not with risk of coronary heart disease , 2006, Clinical genetics.

[43]  B. Wolffenbuttel,et al.  An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study. , 2006, The Journal of clinical endocrinology and metabolism.

[44]  R. Clark.  Raising high-density lipoprotein with cholesteryl ester transfer protein inhibitors. , 2006, Current opinion in pharmacology.

[45]  P. Barter,et al.  Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. , 2006, Journal of the American College of Cardiology.